All In Biotech

Drug Trial Radar · NCT07094087

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

A Phase 3, Multicenter, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Apr 6, 2027

Study completion May 5, 2027

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, randomized, open-label, parallel-group, controlled study to assess the efficacy and safety of BE1116 compared with fresh frozen plasma (FFP) in adult participants undergoing complex cardiovascular surgery with CPB. The primary purpose of the study is to compare the efficacy of BE1116 and FFP in correcting coagulation factor deficiencies in bleeding participants undergoing complex cardiovascular surgery with CPB.

Conditions

  • Complex Cardiovascular Surgery With Cardiopulmonary Bypass

Interventions

  • BE1116Biological

    A single dose of BE1116 will be administered by intravenous (IV) infusion intraoperatively.

  • FFPBiological

    A single dose of FFP will be administered as investigational product (IP) by IV infusion intraoperatively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With and Without a Successful Correction of Coagulation Factor DeficiencyTime frame: At Day 1 after IP infusion (30 minutes after the end of infusion)

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • UCLA Health - Ronald Reagan Medical Center

    Los Angeles, California · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Not yet recruiting

  • University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas · Not yet recruiting

  • University of Maryland Medical Center (UMMC)

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Medicine

    Baltimore, Maryland · Not yet recruiting

  • Cooper University Healthcare

    Camden, New Jersey · Not yet recruiting

  • North Shore University Hospital

    Manhasset, New York · Not yet recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • OUHSC (University of Oklahoma Health Sciences Center)

    Oklahoma City, Oklahoma · Recruiting

  • Oregon Health & Sciences University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center (VUMC)

    Nashville, Tennessee · Not yet recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Not yet recruiting

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

  • Kingston Health Science Center

    Kingston, Ontario, Canada · Not yet recruiting

  • London Health Sciences Center - University Campus

    London, Ontario, Canada · Recruiting

  • University of Toronto - St. Michael's Hospital (SMH) - Keenan Research Centre for Biomedical Science

    Toronto, Ontario, Canada · Recruiting

  • Universite de Montreal-Institut de Cardiologie de Montreal (ICM) Montreal Heart Institute (MHI)

    Montreal, Quebec, Canada · Recruiting

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan · Recruiting

  • National Cerebral and Cardiovascular Center

    Suita, Osaka, Japan · Recruiting

  • Sakakibara Heart Institute

    Fuchu-shi, Tokyo, Japan · Recruiting

  • Hospital Civil de Guadalajara

    Guadalajara, Jalisco, Mexico · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.